BioSeek

NEW YORK (GenomeWeb News) – DiscoveRx today said that it has acquired BioSeek, maker of the BioMAP platform of cell-based disease models for drug screening.
Financial terms of the deal were not disclosed.

NEW YORK (GenomeWeb News) – BioSeek today said that the US Environmental Protection Agency has extended the firm's contract to participate in the ToxCast screening program.

A research team led by scientists at proteomics firm Cellzome has developed a selective inhibitor to the PI3 kinase isoform PI3Kγ.

Cellzome will use the BioMap platform in its inflammatory disease drug discovery projects.

BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.

The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.

BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.

The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.

The firm will profile compounds for the second phase of the EPA initiative.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.